Sanctuary Advisors LLC Takes $605,000 Position in HealthEquity, Inc. $HQY

Posted by Francis Steltz on Aug 30th, 2026

Sanctuary Advisors LLC bought a new position in HealthEquity, Inc. (NASDAQ:HQY – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 6,695 shares of the company’s stock, valued at approximately $605,000.

A number of other large investors have also recently made changes to their positions in HQY. BlackRock Inc. bought a new stake in HealthEquity in the 2nd quarter worth approximately $1,018,621,000. Wasatch Advisors LP lifted its holdings in HealthEquity by 10.5% in the 2nd quarter. Wasatch Advisors LP now owns 7,960,735 shares of the company’s stock worth $719,014,000 after purchasing an additional 757,801 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of HealthEquity by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 2,201,232 shares of the company’s stock worth $201,685,000 after acquiring an additional 5,671 shares during the last quarter. Westfield Capital Management Co. LP boosted its holdings in shares of HealthEquity by 13.7% during the 4th quarter. Westfield Capital Management Co. LP now owns 1,952,452 shares of the company’s stock valued at $178,864,000 after purchasing an additional 235,794 shares during the last quarter. Finally, William Blair Investment Management LLC bought a new position in HealthEquity during the fourth quarter valued at approximately $169,956,000. 99.55% of the stock is currently owned by institutional investors.

HealthEquity Trading Up 3.2%

NASDAQ HQY opened at $96.37 on Friday. The company has a fifty day simple moving average of $98.16 and a two-hundred day simple moving average of $87.87. HealthEquity, Inc. has a 12-month low of $72.76 and a 12-month high of $107.62. The company has a current ratio of 2.99, a quick ratio of 3.44 and a debt-to-equity ratio of 0.47. The stock has a market cap of $8.06 billion, a P/E ratio of 34.79, a P/E/G ratio of 1.62 and a beta of 0.21.

HealthEquity (NASDAQ:HQY – Get Free Report) last announced its quarterly earnings data on Thursday, August 27th. The company reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.05. HealthEquity had a return on equity of 15.33% and a net margin of 17.36%.The firm had revenue of $350.73 million during the quarter, compared to analysts’ expectations of $349.22 million. HealthEquity’s revenue was up 95.5% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. On average, analysts forecast that HealthEquity, Inc. will post 3.92 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Citizens Jmp increased their price objective on shares of HealthEquity from $110.00 to $111.00 and gave the company a “market outperform” rating in a research report on Monday, June 1st. Wall Street Zen upgraded HealthEquity from a “hold” rating to a “buy” rating in a report on Saturday, August 22nd. Weiss Ratings raised shares of HealthEquity from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, June 5th. Wells Fargo & Company set a $111.00 price target on HealthEquity in a research report on Monday, June 1st. Finally, KeyCorp reiterated an “overweight” rating on shares of HealthEquity in a research note on Tuesday, May 26th. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, HealthEquity presently has an average rating of “Moderate Buy” and a consensus price target of $110.93.

Get Our Latest Research Report on HQY

Insider Buying and Selling at HealthEquity

In other HealthEquity news, Director Adrian T. Dillon sold 7,632 shares of the stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $104.61, for a total transaction of $798,383.52. Following the sale, the director directly owned 62,395 shares of the company’s stock, valued at approximately $6,527,140.95. This trade represents a 10.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Henry Fiore sold 2,354 shares of the firm’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $95.00, for a total value of $223,630.00. Following the sale, the executive vice president directly owned 52,244 shares in the company, valued at approximately $4,963,180. This trade represents a 4.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 12,456 shares of company stock worth $1,256,664. 1.60% of the stock is owned by corporate insiders.

Key Headlines Impacting HealthEquity

Here are the key news stories impacting HealthEquity this week:

Positive Sentiment: HealthEquity exceeded expectations with adjusted earnings of $1.24 per share versus the $1.19 consensus, while revenue reached $350.7 million, slightly above estimates. Revenue increased 95.5% year over year. HealthEquity Q2 Earnings and Revenues Top Estimates
Positive Sentiment: Profitability improved, with net income rising 10% to $65.6 million and net margin expanding to 19% from 18%. Adjusted EBITDA grew 11% to $167 million, while its margin increased to 48% from 46%. HealthEquity Second-Quarter Financial Results
Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $4.66–$4.73, above the $4.56 analyst consensus. Record HSA assets of $37.9 billion provide additional support for the company’s long-term growth outlook. HealthEquity Raises Fiscal 2027 Guidance
Positive Sentiment: BTIG Research reaffirmed its “buy” rating and raised its price target to $115. Another analysis indicated that HQY could be approximately 19% undervalued after the guidance increase, reinforcing the bullish interpretation of the earnings update. BTIG Research Rating HealthEquity Could Be Undervalued
Neutral Sentiment: Fiscal 2027 revenue guidance of approximately $1.4 billion was broadly in line with expectations, so the guidance improvement was driven mainly by stronger anticipated earnings and margins.
Negative Sentiment: Director Adrian T. Dillon sold 7,632 shares valued at approximately $798,000, reducing his position by 10.9%. The sale was executed under a pre-arranged Rule 10b5-1 plan, which reduces its negative signaling value but could still attract investor attention. HealthEquity Director Stock Sale
Negative Sentiment: HQY trades at a premium valuation of roughly 35 times earnings. After the recent advance toward its 52-week high, some investors may lock in gains, potentially tempering the stock’s reaction to otherwise favorable fundamentals.

About HealthEquity

(Free Report)

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.